The recent surge in investments into niche pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Investor Pharma." While the potential for blockbuster treatments and impressive returns is clear, the connected risks are also notable. Many of these en